Searching over 5,500,000 cases.

Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.

In re CV Sciences, Inc. Securities Litigation

United States District Court, D. Nevada

December 10, 2019

In Re: CV Sciences, Inc. Securities Litigation



         This is a securities-fraud-class-action lawsuit against CV Sciences, Inc. and its current and former officers Michael Mona, Jr., Michael Mona, III, and Joseph D. Dowling. CV Sciences is a life-science company that specializes in cannabidiols (CBD).[1] CV Sciences' pharmaceutical division developed a treatment utilizing CBD for smokeless tobacco use and addiction.[2] The company filed a patent application for the product with the United States Patent and Trade Office (USPTO), [3] and the defendants subsequently made numerous public statements that the product was “patent-pending, ” “patent-protectable, ” and “proprietary.”[4] But CV Sciences did not reveal that USPTO had rejected its patent application twice-including a “Final Rejection” on grounds that the invention was obvious.[5] After non-party Citron Research shared news of the rejections on Twitter, CV Sciences' stock price dropped 54.24%.[6]

         Lead Plaintiff Richard Ina and others filed suit, alleging that the defendants violated section 10(b) of the Securities Exchange Act of 1934 (the Exchange Act), 15 U.S.C. § 78j(b), and Securities and Exchange Commission (SEC) Rule 10b-5, 17 C.F.R. § 240.10b-5, by describing the product as “patent-pending, ” “patent-protectable, ” and “proprietary” in the wake of the rejections. Ina also asserts control-person liability against the individual defendants under section 20(b) of the Exchange Act. The defendants move to dismiss Ina's amended complaint on numerous grounds. Ina moves to strike certain exhibits to the defendants' motion to dismiss. I grant the motion to strike in part. But I deny the motion to dismiss because the briefing on the motion makes clear that the veracity of the defendants' claims that their product was “patent-pending, ” “patent-protectable, ” and “proprietary” cannot be determined as a matter of law on a motion to dismiss, and the defendants' remaining arguments do not merit dismissal.


         I. Motion to strike (ECF No. 44)

         Ina moves to strike eighteen of the nineteen exhibits the defendants filed in support of their motion to dismiss, all references to the exhibits in the motion to dismiss, and “unsworn attorney testimony” in the motion to dismiss.[7] The defendants respond that all of the challenged exhibits are subject to judicial notice or incorporation by reference into Ina's amended complaint.[8]

         Courts “must consider . . . documents incorporated into the complaint by reference, and matters of which a court may take judicial notice” while assessing the sufficiency of securities- fraud allegations like Ina's.[9] The incorporation-by-reference doctrine “prevents plaintiffs from selecting only portions of documents that support their claims, while omitting portions of those very documents that weaken-or doom-their claims.”[10] The doctrine applies when (1) “the complaint necessarily relies upon the document” or (2) “the contents of the document are alleged in the complaint, the document's authenticity is not in question, ” and the document's relevance is not in dispute.[11] “But the mere mention of the existence of a document is insufficient to incorporate the contents of a document.”[12] Additionally, under Federal Rule of Evidence 201, courts may take judicial notice of a fact if it is “not subject to reasonable dispute, ” meaning that it “is generally known within the trial court's territorial jurisdiction” or “can be accurately and readily determined from sources whose accuracy cannot reasonably be questioned.”[13]

         Exhibits A through D include: (1) a version of Citron Research's Twitter page that does not include the August 20, 2018, Tweet alleged in the complaint and (2) Wikipedia and New York Times articles about Citron Research's founder and Citron Research's web page, which are linked from the Twitter page.[14] Incorporation by reference of the Twitter page, which does not include the Tweet referenced in the complaint, is not appropriate because it would not serve the doctrine's purpose of ensuring appropriate context for documents alleged in the complaint.[15] I will not incorporate web pages and articles linked from that Twitter page into the complaint because such an extension of the doctrine would permit incorporation of, among other things, the New York Times wedding section into a complaint that quotes a New York Times article. And although these web pages and articles may be judicially noticed to “indicate what was in the public realm at the time, ”[16] the defendants use them in their motion to dismiss to support factual assertions.[17] So I grant the motion to strike Exhibits A-D and references to these exhibits in the motion to dismiss.

         Exhibit E is a USPTO web page showing the status of CV Sciences' patent application.[18]This document is incorporated by reference because it provides necessary context to the amended complaint's citations to the same website for selective events in the patent application history. And this USPTO patent application web site is also subject to judicial notice.[19] So I deny the motion to strike Exhibit E.

         Exhibits F through R are press releases, a presentation, an investor-call transcript, and documents filed with the SEC containing the statements that Ina alleges were false and misleading.[20] These documents are incorporated by reference into the complaint because they are the basis of Ina's claims.[21] They do not “merely create a defense”[22] because, in addition to the cautionary language cited by defendants in their safe harbor defense, they contain the allegedly false or misleading statements at issue in this case. So I deny the motion to strike Exhibits F-R.[23]

         As to Ina's remaining arguments, I address the motion to strike citations to a law review article and patent treatise below. I deny the motion to strike “unsworn attorney testimony” in the motion to dismiss because I find that these “factual representations” consist of argument or are based on exhibits to the motion to dismiss. And I deny Ina's request to convert the motion to dismiss into a motion for summary judgment because courts must consider documents subject to judicial notice or incorporation by reference while assessing the sufficiency of securities-fraud allegations.[24]

         II. Motion to dismiss (ECF No. 44)

         Section 10(b) of the Exchange Act prohibits the use of “any manipulative or deceptive device or contrivance” related to the purchase or sale of securities when the use violates the regulations promulgated by the SEC.[25] Under SEC Rule 10b-5, it is unlawful for any person “[t]o make any untrue statement of fact or to omit to state a material fact necessary in order to make the statements made, in the light of the circumstances under which they were made, not misleading.”[26] “To recover damages for violations of section 10(b) and Rule 10b-5, a plaintiff must prove (1) a material misrepresentation or omission by the defendant; (2) scienter; (3) a connection between the misrepresentation or omission and the purchase or sale of a security; (4) reliance upon the misrepresentation or omission; (5) economic loss; and (6) loss causation.”[27]

         At the pleading stage, a complaint alleging violations of Section 10(b) of the Exchange Act and SEC Rule 10b-5 must meet both the heightened pleading requirements for fraud claims under Federal Rule of Civil Procedure 9(b) and the “exacting pleading requirements of the Private Securities Litigation Reform Act” (PSLRA), 15 U.S.C. § 78u-4(b)(2)(A).[28] Rule 9(b) requires that the complaint “state with particularity the circumstances constituting fraud, ”[29]including “including the who, what, when, where, and how of the misconduct charged.”[30] The PSLRA requires that the complaint “state with particularity facts giving rise to a strong inference that the defendant acted with the required state of mind.”[31]

         A. Material misrepresentations

         Ina must “specify each statement alleged to have been misleading, [and] the reason or reasons why the statement is misleading” to adequately plead material misrepresentation.[32]“Although determining materiality in securities fraud cases should ordinarily be left to the trier of fact, conclusory allegations of law and unwarranted inferences are insufficient to defeat a motion to dismiss for failure to state a claim.”[33] “Rule 10b-5 [prohibits] only misleading and untrue statements, not statements that are incomplete . . . . Often, a statement will not mislead even if it is incomplete or does not include all relevant facts.”[34] “Instead, ‘a statement is misleading if it would give a reasonable investor the impression of a state of affairs that differs in a material way from the one that actually exists.'”[35]

         With respect to opinion statements, when a plaintiff relies on a theory that such a statement is a material misrepresentation, “the plaintiff must allege both that ‘the speaker did not hold the belief she professed' and that the belief is objectively untrue.”[36] “[W]hen a plaintiff relies on a theory of omission, the plaintiff must allege ‘facts going to the basis for the issuer's opinion . . . whose omission makes the opinion statement at issue misleading to a reasonable person reading the statement fairly and in context.'”[37] However, a “mildly optimistic, subjective assessment hardly amounts to a securities violation, ” so courts must distinguish material misrepresentations from “puffery.”[38] “Statements by a company that are capable of objective verification are not puffery and can constitute material misrepresentations.”[39]

         The defendants argue that their challenged statements were neither false nor material because the patent application process often extends beyond a final rejection by the USPTO.[40]Additionally, the defendants argue that describing its product as “proprietary” was non-actionable puffery.[41] Ina responds that after receiving the USPTO rejections, defendants' characterizations of the product as “patent-pending” were materially misleading statements of fact and their claims that the product was “patent-protectable” and “proprietary” were misleading opinions.

         The issue boils down to whether a reasonable investor would believe that a patent remains pending after a final rejection but before potential appeals have been exhausted. If so, then the defendants' statements that their product was “patent-pending, ” “patent-protectable, ” and “proprietary” were not misleading under the standards outlined above. The parties primarily rely on statistical analysis of the patent-application process to resolve the issue: (1) Ina alleges that a “comprehensive study from 1996 to 2005 found that only 41.4% of USPTO decisions that finally reject a patent are overturned by the Patent Trial and Appeal Board” and that “the percentage of USPTO decisions that finally rejected patent applications that were overturned by the Patent Trial and Appeal Board [subsequently] decreased to 39.3% (2013), 31.3% (2014), 28.9% (2015), 28.6% (2016), 29.5% (2017), and 28.3% (2018);”[42] while (2) the defendants cite a law review article concluding that “more than half of those applications that received a final rejection [ ] ultimately resulted in patents” after amendments and appeals.[43] But the parties' reliance on dueling statistics makes it clear that I cannot resolve this issue as a matter of law on a motion to dismiss.

         The U.S. District Court for the Southern District of New York's decision in Alpha Capital Anstalt v. New Generation Biofuels, Inc. is instructive.[44] In that case, the plaintiff alleged that the defendants made statements discussing their “portfolio of patented and patent-pending technology” despite having received negative feedback on their patent claims in “[f]oreign [p]atent [r]eports.”[45] Even though these preliminary reports were seemingly less conclusive than the USPTO's final rejection here, the court denied the motion to dismiss because several factual questions remained, including the significance of the reports.[46] In that case, the court had the benefit of expert declarations on the patent-application process.[47] So, in this context, determining whether the challenged statements were materially misleading requires discovery and expert testimony, which exceeds the scope of a proper dismissal inquiry.[48] For purposes of this motion, it is enough that Ina identifies the misleading statements with particularity and alleges why they are misleading, meeting the requirements of Rule 9(b) and the PSLRA. I therefore deny the motion to dismiss on this ground.[49]

         B. Truth-on-the-market defense

         The defendants argue that the truth-on-the-market defense bars Ina's claims because the patent rejections were posted on the USPTO's website.[50] Ina responds that a reasonable investor would not have known the information, the defendants' misstatements counterbalanced the information, and the stock drop after the Citron Research Tweet undermines the defense.[51]

         The Ninth Circuit has held that the truth-on-the-market defense excuses a “failure to disclose material information . . . where that information has been made credibly available to the market by other sources.”[52] However, “any material information [that] insiders fail to disclose must be transmitted to the public with a degree of intensity and credibility sufficient to effectively counter-balance any misleading impression created by the insiders' one-sided representations.”[53] Accordingly, “the truth-on-the-market defense is intensely fact-specific, so courts rarely dismiss a complaint on this basis.”[54]

         Ina alleges that the defendants repeatedly reassured investors over an extended period of time that their product was “patent-pending, ” “patent-protectable, ” and “proprietary.” I cannot conclude at this time that the publication of the patent rejections on the USPTO website were sufficient to counter-balance the impression created by these representations. So I deny the motion to dismiss on this ground.

         C. Scienter

         The defendants also content that Ina fails to adequately plead scienter because his theory that the individual defendants stood to gain from a stock bonus is insufficient.[55] Ina responds that his allegations regarding the defendants' knowledge or reckless disregard of the rejections, the core-operations doctrine, allegations of past wrongdoing by Mona Jr., and certain defendants' signed Sarbanes-Oxley Act certifications are sufficient to establish scienter.[56]

         Under the PSLRA, plaintiffs must “state with particularity facts giving rise to a strong inference that the defendant acted with the required state of mind.”[57] The “required state of mind is a mental state that not only covers intent to deceive, manipulate, or defraud, but also deliberate recklessness.”[58] “[D]eliberate recklessness is an extreme departure from the standards of ordinary care . . . which presents a danger of misleading buyers or sellers that is either known to the defendant or is so obvious that the actor must have been aware of it.”[59] To assess whether a plaintiff's allegations meet this standard, courts “must ask: When the allegations are accepted as true and taken collectively, would a reasonable person deem the inference of scienter at least as strong as any opposing inference?”[60] The absence of an allegation that the defendants had a pecuniary motive to commit fraud is not fatal.[61]

         Most importantly, the defendants concede in reply that they had knowledge of the patent rejections and that the core-operations doctrine, which permits the court to infer “that facts critical to a business's core operations . . . are known to a company's key officers, ” applies.[62] So the defendants knew that the patent application had been rejected twice-including with a “final rejection” on grounds that the product was obvious-when they made statements that the product was “patent-pending, ” “patent-protectable, ” and “proprietary.” Because plaintiff alleges with requisite particularity that these statements were materially misleading and, as discussed above, I cannot determine otherwise as a matter of law on a motion to dismiss, defendants' knowledge of the rejections constitutes, at the very least, deliberate recklessness as to whether the subsequent statements would mislead investors. The defendants' knowledge of the rejections thus raises a strong inference of scienter on its own, and it is at least as strong as any opposing inference that the defendants lacked the requisite state of mind. So I do not address the other allegations supporting scienter and deny the motion to dismiss on this ground.

         D. Loss causation

         To adequately plead loss causation, the plaintiffs “must allege that the defendant's share price fell significantly after the truth became known.”[63] “Because loss causation is simply a variant of proximate cause, the ultimate issue is whether the defendant's misstatement, as opposed to some other fact, foreseeably caused the plaintiff's loss.”[64] Ina is, of course, not required to prove loss causation at the pleading stage, but he “must properly allege it.”[65]“[B]asic economic principles preclude dismissing a complaint” on grounds that the stock price recovered after falling significantly because the rebound can often be explained by external events.[66]

         Ina alleges that CV Sciences' share price fell significantly-52.4%-in the hours after the Citron Research Tweet revealing that the patent application had been twice rejected.[67]Because the Tweet revealed the same information withheld from the allegedly misleading statements, Ina sufficiently alleges that the defendants' fraudulent conduct proximately caused his loss. And although the stock price rebounded in subsequent days, dismissal on those grounds is not appropriate because other events could have caused that recovery. So I deny the motion to dismiss on loss-causation grounds.

         E. PSLRA damages limitation

         The defendants next argue that because CV Sciences' stock price recovered after the initial fall, class-action plaintiffs who purchased shares on or prior to August 8, 2018, cannot establish loss causation under a damages-limitation provision in the PSLRA.[68] Ina responds that the defendants confuse loss causation for damages and that dismissal on these grounds is inappropriate.[69]

         15 U.S.C. § 78u-4(e) provides that “the award of damages to the plaintiff shall not exceed the difference between the purchase or sale price . . . and the mean trading price of that security during the 90-day period beginning on the date on which the information correcting the misstatement or omission that is the basis for the action is disseminated to the market.”[70] Under this provision, “if the mean trading price of a security during the 90-day period following the correction is greater than the price at which the plaintiff purchased his stock then that plaintiff would recover nothing under the PSLRA's limitation on damages.”[71]

         The parties have not identified any authority applying this damages-limitation provision on a motion to dismiss a Section 10(b) claim. Application of 15 U.S.C. § 78u-4(e) is more appropriate on a class-certification or summary-judgment motion, when I may have the benefit of expert testimony on damages.[72] So I deny without prejudice the motion to dismiss on this ground.

         F. Forward-looking statements

         The PSLRA contains a safe harbor provision that “exempts, under certain circumstances, a forward-looking statement, which is ‘any statement regarding (1) financial projections, (2) plans and objectives of management for future operations, (3) future economic performance, or (4) the assumptions underlying or related to any of these issues.'”[73] “But the safe harbor is not designed to protect companies and their officials when they knowingly make a materially false or misleading statement about current or past facts.”[74] “The safe harbor applies if the forward-looking statement is . . . identified as a forward-looking statement, and is accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those in the forward-looking statement . . . .”[75]

         Although the statements at issue were accompanied by appropriate cautionary language, none of these statements were forward-looking. The claims that the product was “patent-pending” refer to current facts. The statements that the product was “patent-protectable” and “proprietary” may appear forward-looking on their face, but Ina alleges that the contingency these statements refer to was already resolved when these statements were made-by the patent rejections. So these statements also refer to current or past events, and I deny the motion to dismiss on this ground as well.

         G. Section 20(a)

         Section 20(a) of the PSLRA establishes joint and several liability for controlling persons who aid and abet securities violations.[76] To establish control-person liability, the plaintiffs must allege “a primary violation of federal securities law” and that “the defendant exercised actual power or control over the primary violator.”[77] The defendants only move to dismiss on grounds that Ina failed to allege a primary violation of federal securities law.[78] Because I find that Ina sufficiently alleges a violation of federal securities law, I deny the motion to dismiss on this ground as well.

         H. ...

Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.